Description: Memphasys Limited, formerly NuSep Holdings Limited, is a bio-separations company developing and commercializing separation techniques based on its membrane technology. The Company has two main areas of focus for separating biological substances from fluids, utilizing its separation membranes and equipment: SpermSep and Hydrogel polymer membrane technology development. Its segments include Separations and Corporate. The Separations segment develops and markets the PrIME technology in both the commercial and research markets, including the ProteomeSep and SpermSep devices. Its program, SpermSep, separates the sperm from a semen sample using electrophoresis and specialist membranes. The SpermSep technology is used in fertility treatments, including in vitro fertilization (IVF) for humans and in various artificial reproductive techniques (ART) for animals. It has developed a polymer membrane separation technology using polyacrylamide hydrogel membranes with electrophoresis.
Home Page: www.memphasys.com
MEM Technical Analysis
MFS SERIES TRUST X
,
Phone:
800-225-2606
Officers
| Name | Title |
|---|---|
| Ms. Alison Mary Coutts B.E., B.E. (Chem), GDipBiotech, M.B.A., MBA | MD, CEO & Director |
| Pablo Neyertz | Director of Fin. |
| Nick Gorring | Operations Mang. |
| Mr. Malcolm Coleman | Chief Financial Officer of Nusep Ltd |
| Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD | Company Sec. |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6313 |
| Price-to-Sales TTM: | 165.5405 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |